The year in cardiology 2018: valvular heart disease
█ Current opinion
Wojciech Wojakowski1 and Helmut Baumgartner2
1Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Ziołowa 45, 40-635 Katowice, Poland; E-mail: email@example.com
2Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital Muenster, Albert Schweitzer Campus 1, Building A1, 48149 Muenster, Germany
Tel.: +49 251 834 6110, Fax: +49 251 834 6109; E-mail: firstname.lastname@example.org
In 2018 the publications on valvular heart disease (VHD) addressed all topics – epidemiology, diagnosis, therapy and predictors of outcome – but were dominated by studies focusing on transcatheter treatment. Regarding mitral regurgitation (MR) two pivotal studies investigating transcatheter edge-to-edge repair for secondary MR as well as early clinical experience with transcatheter mitral valve replacement (TMVR) were published. Regarding aortic stenosis (AS) there is a clear trend towards the expansion of indications for transcatheter aortic valve implantation (TAVI) to intermediate and low-risk groups, bicuspid aortic valve (BAV) and failed surgically implanted bioprostheses. Tricuspid valve (TV) disease is a growing clinical problem associated with high morbidity and mortality. Isolated TV surgery has a high risk and is currently performed in a minority of patients. Novel therapies using the edge-to-edge approach or annuloplasty are being investigated.